pharma · Amyotrophic Lateral Sclerosis · Acute Myeloid Leukemia
AB Science drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
AB Science drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
Development asset linked to AB Science in public FDA and regional records.
Antineoplastic and immunomodulating agents (L01) compound in AB Science's portfolio. Molecular target: Fibroblast growth factor receptor 3.
Development asset linked to AB Science in public FDA and regional records.
Development asset linked to AB Science in public FDA and regional records.
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
Development asset linked to AB Science in public FDA and regional records.
Development asset linked to AB Science in public FDA and regional records.
Development asset linked to AB Science in public FDA and regional records.
Development asset linked to AB Science in public FDA and regional records.
US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.